Ardelyx Inc (ARDX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Ardelyx Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 5.00 $ — 21% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 98.4% passed
- More than 10% revenue growth is expected for the coming year 36.0% passed
- Share count grows by less than 3% a year 15.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 11.3% failed
- Gross margin at 40% or higher and without meaningful erosion 89.5% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 53 m net cash passed
- Operating cash flow covers the profits of the last three years -10 m failed
- Return on capital at 15% or higher, or up versus two years ago -9.9% failed
- Insiders hold at least 10% or are net buyers 3.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 226.0% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 11
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.05 | -0.16 – 0.02 | 541 | 80.0% | 7 |
| 12/31/2027 | 0.52 | 0.31 – 0.74 | 740 | 1,088.3% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.05 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.02 | – | 116 | 237.90 | 4.00 | 10 | 9 |
| 2025: Q1 | -0.17 | – | 74 | 61.00 | -55.50 | -39 | -39 |
| 2025: Q2 | -0.08 | – | 98 | 33.40 | -19.50 | -25 | -26 |
| 2025: Q3 | 0.00 | – | 110 | 12.30 | -0.90 | 0 | 0 |
| 2025: Q4 | 0.00 | -108.80 | 125 | 7.80 | -0.30 | 21 | 21 |
| 2026: Q1 | -0.15 | – | 95 | 27.50 | -39.80 | -32 | -32 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 24 | -113 | -112 | -2.80 | -93 | 193 | 213 |
| 2017 | 42 | -65 | -64 | -1.36 | -65 | 139 | 158 |
| 2018 | 3 | -91 | -91 | -1.62 | -70 | 116 | 183 |
| 2019 | 5 | -91 | -95 | -1.47 | -76 | 187 | 260 |
| 2020 | 8 | -91 | -94 | -1.05 | -81 | 126 | 202 |
| 2021 | 10 | -154 | -158 | -1.52 | -153 | 83 | 150 |
| 2022 | 52 | -64 | -67 | -0.42 | -70 | 98 | 190 |
| 2023 | 124 | -63 | -66 | -0.30 | -90 | 167 | 298 |
| 2024 | 334 | -28 | -39 | -0.17 | -45 | 173 | 436 |
| 2025 | 407 | -41 | -62 | -0.26 | -42 | 167 | 502 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Ardelyx, Inc. entdeckt, entwickelt und vermarktet Medikamente zur Behandlung ungedeckten medizinischen Bedarfs in den USA und international.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 489 |
| Headquarters | Waltham, MA |
| Address | 400 Fifth Avenue, 02451 Waltham, United States |
| Phone | 510 745 1700 |
| Website | ardelyx.com |
| IPO Date | 19. Jun 2014 |
| ISIN | US0396971071 |
| Stock Split | 4:1 on 07/20/2021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Michael G. Raab | President, CEO & Director | 1965 |
| Sue Hohenleitner | Chief Financial Officer | 1971 |
| John Bishop Ph.D. | Chief Technical & Quality Officer | 1962 |
| Joseph Reilly | Senior VP of Finance & Principal Accounting Officer | 1974 |
| Caitlin Lowie | Vice President of Corporate Communications & Investor Relations | – |
| Felecia W. Ettenberg | Chief Legal Officer | 1971 |
| James P. Brady | Chief Human Resources Officer | 1971 |
| Laura A. Williams M.D., M.P.H. | Chief Patient Officer & Interim Chief Medical Officer | 1963 |
| Mike Kelliher | Chief Business Officer | 1977 |
| Eric Duane Foster | Chief Commercial Officer | 1975 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Raab Michael | President & CEO | Sell | 41,668 | 5.06 | 210,923 |
| 15. Jul 2026 | Raab Michael | President & CEO | Other | 20,834 | 0.99 | 20,626 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.